Header Logo

Katherine Griem

Concepts (153)

Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.


Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Breast Neoplasms
18
2017
409
2.110
Why?
Brachytherapy
10
2017
56
1.470
Why?
Radiation Injuries
3
2012
32
1.080
Why?
Radiotherapy Planning, Computer-Assisted
5
2017
68
0.930
Why?
Radiotherapy, Conformal
5
2011
21
0.920
Why?
Skin
2
2012
116
0.760
Why?
Mastectomy, Segmental
8
2009
33
0.670
Why?
Radiotherapy Dosage
14
2017
117
0.520
Why?
Radiotherapy, Adjuvant
5
2017
52
0.460
Why?
Radiometry
4
2017
41
0.450
Why?
Carcinoma, Ductal, Breast
4
2008
34
0.430
Why?
Prone Position
2
2011
36
0.420
Why?
Thermal Conductivity
1
2012
3
0.410
Why?
Thermography
1
2012
14
0.400
Why?
Radiotherapy, Intensity-Modulated
2
2009
38
0.390
Why?
Lymph Nodes
2
2011
70
0.390
Why?
Breast
3
2010
26
0.370
Why?
Combined Modality Therapy
12
2010
307
0.340
Why?
Genital Neoplasms, Female
1
2010
14
0.340
Why?
Heart
2
2009
69
0.340
Why?
Axilla
2
2008
13
0.330
Why?
Taxoids
1
2009
10
0.320
Why?
Radiodermatitis
1
2009
4
0.320
Why?
Female
25
2012
15730
0.310
Why?
Antineoplastic Agents
2
2009
190
0.310
Why?
Middle Aged
18
2011
9269
0.240
Why?
Humans
31
2017
28436
0.230
Why?
Posture
1
2003
66
0.220
Why?
Head and Neck Neoplasms
4
1997
151
0.190
Why?
Carcinoma, Squamous Cell
4
1997
177
0.190
Why?
Adult
17
2011
8107
0.190
Why?
Feasibility Studies
3
2011
232
0.180
Why?
Aged
15
2011
9277
0.180
Why?
Intraoperative Care
2
2017
43
0.160
Why?
Lymph Node Excision
2
1996
27
0.160
Why?
Supine Position
2
2011
21
0.150
Why?
Radiography
4
2009
640
0.150
Why?
Mice
2
2012
1461
0.150
Why?
Treatment Failure
2
2008
163
0.140
Why?
Retrospective Studies
7
2013
3612
0.130
Why?
Lung
3
2011
170
0.130
Why?
Neoplasm Staging
4
2010
371
0.130
Why?
Animals
2
2012
3780
0.110
Why?
Imaging, Three-Dimensional
2
2006
199
0.110
Why?
Accreditation
1
2013
15
0.110
Why?
Radiation Oncology
1
2013
14
0.110
Why?
Pilot Projects
3
2012
440
0.100
Why?
Body Water
1
2012
3
0.100
Why?
Mice, Hairless
1
2012
3
0.100
Why?
Tomography
1
2012
13
0.100
Why?
Education, Medical, Graduate
1
2013
77
0.100
Why?
Fluorouracil
5
1999
46
0.100
Why?
Physicians
1
2013
124
0.090
Why?
Iridium Radioisotopes
2
2008
4
0.090
Why?
Logistic Models
1
2012
396
0.090
Why?
Electronics
2
2010
11
0.090
Why?
Monte Carlo Method
2
2017
53
0.090
Why?
Clinical Competence
1
2013
249
0.090
Why?
Antineoplastic Combined Chemotherapy Protocols
6
1997
241
0.090
Why?
Disease-Free Survival
3
2007
177
0.090
Why?
Internship and Residency
1
2013
219
0.080
Why?
Treatment Outcome
6
2010
3615
0.080
Why?
Neoplasm Recurrence, Local
6
1996
206
0.080
Why?
Radioisotope Teletherapy
1
1989
1
0.080
Why?
Contracture
1
2009
14
0.080
Why?
Cisplatin
4
1997
52
0.080
Why?
Neoplasms, Radiation-Induced
1
1989
12
0.080
Why?
Organ Size
1
2009
100
0.080
Why?
Liposarcoma
1
1989
17
0.080
Why?
Biomarkers
1
2012
596
0.080
Why?
Lymphatic Metastasis
2
2008
90
0.080
Why?
Thyroid Neoplasms
1
1989
44
0.080
Why?
Rectal Neoplasms
1
1989
14
0.080
Why?
Carcinoma, Lobular
2
2007
21
0.080
Why?
Heart Ventricles
1
2009
115
0.080
Why?
Follow-Up Studies
7
2010
1859
0.080
Why?
Models, Biological
2
2004
326
0.080
Why?
Carcinoma in Situ
1
2007
10
0.070
Why?
Mastectomy
1
1987
37
0.070
Why?
Aged, 80 and over
5
2009
4857
0.070
Why?
Tomography, X-Ray Computed
3
2007
730
0.070
Why?
Cell Division
2
1996
83
0.060
Why?
Electrons
1
2004
21
0.060
Why?
Reference Values
1
2003
194
0.050
Why?
Chemotherapy, Adjuvant
3
1996
81
0.050
Why?
Time Factors
4
1996
1491
0.040
Why?
S Phase
2
1996
10
0.040
Why?
Antimetabolites, Antineoplastic
1
1999
17
0.040
Why?
Tongue Neoplasms
1
1999
19
0.040
Why?
Ventricular Dysfunction, Left
1
1999
46
0.040
Why?
Carcinoma
1
1999
69
0.040
Why?
Antineoplastic Agents, Hormonal
2
1996
18
0.040
Why?
Tamoxifen
2
1996
28
0.040
Why?
Biopsy
2
1996
220
0.040
Why?
Neoplasm Invasiveness
2
1995
89
0.040
Why?
Water
1
2017
32
0.040
Why?
Dose-Response Relationship, Radiation
2
2007
10
0.030
Why?
Mouth Mucosa
1
1996
13
0.030
Why?
Paclitaxel
1
1996
44
0.030
Why?
Cell Count
1
1996
79
0.030
Why?
Cellulitis
1
1996
10
0.030
Why?
Esophageal Neoplasms
1
1997
54
0.030
Why?
Adenocarcinoma
1
1997
147
0.030
Why?
Immunohistochemistry
1
1996
362
0.030
Why?
Apoptosis
1
1996
205
0.030
Why?
Cell Cycle
1
1995
34
0.030
Why?
Male
7
1999
15291
0.030
Why?
Survival Rate
1
1995
356
0.030
Why?
Neoplasms, Second Primary
1
1994
40
0.030
Why?
Postoperative Care
2
1996
139
0.030
Why?
Age Factors
1
1995
781
0.030
Why?
Hodgkin Disease
1
1993
17
0.030
Why?
Safety
1
2010
45
0.020
Why?
Cobalt Radioisotopes
1
1989
3
0.020
Why?
Nasopharyngeal Neoplasms
1
1989
3
0.020
Why?
Anal Canal
1
1989
3
0.020
Why?
Child
2
1993
1420
0.020
Why?
Preoperative Care
1
1989
125
0.020
Why?
Statistics as Topic
1
1987
107
0.020
Why?
Hemibody Irradiation
1
2007
2
0.020
Why?
Random Allocation
1
1987
129
0.020
Why?
Tumor Burden
1
2007
28
0.020
Why?
United States
1
2013
2201
0.020
Why?
Survival Analysis
2
1997
267
0.020
Why?
Clinical Trials as Topic
1
1987
239
0.020
Why?
Equipment Design
1
2006
152
0.020
Why?
Relative Biological Effectiveness
1
2004
5
0.010
Why?
Body Burden
1
2004
7
0.010
Why?
Particle Accelerators
1
2004
7
0.010
Why?
Scattering, Radiation
1
2004
37
0.010
Why?
Models, Statistical
1
2004
129
0.010
Why?
Actuarial Analysis
2
1995
8
0.010
Why?
Computer Simulation
1
2004
199
0.010
Why?
Risk Factors
1
1989
2408
0.010
Why?
Heart Diseases
1
1999
71
0.010
Why?
Infusions, Intravenous
1
1997
53
0.010
Why?
Esophagectomy
1
1997
24
0.010
Why?
Carcinoma, Intraductal, Noninfiltrating
1
1996
12
0.010
Why?
Anti-Inflammatory Agents
1
1996
80
0.010
Why?
Idoxuridine
1
1995
2
0.010
Why?
Mitotic Index
1
1995
5
0.010
Why?
G2 Phase
1
1995
4
0.010
Why?
Bromodeoxyuridine
1
1995
10
0.010
Why?
DNA, Neoplasm
1
1995
20
0.010
Why?
Recurrence
1
1996
322
0.010
Why?
Lymphoma
1
1995
38
0.010
Why?
Regression Analysis
1
1995
266
0.010
Why?
Kinetics
1
1995
194
0.010
Why?
Proportional Hazards Models
1
1995
352
0.010
Why?
Contraindications
1
1994
33
0.010
Why?
Anti-Bacterial Agents
1
1996
383
0.010
Why?
Postoperative Complications
1
1996
932
0.010
Why?
Adolescent
1
1993
2307
0.000
Why?
Griem's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (153)
Explore
_
Co-Authors (10)
Explore
_
Similar People (60)
Explore
_
Same Department Expand Description
Explore
_